Structural Formula (Aripiprazole 8524 8525 1)
Aripiprazole Tablet
Product Images NDC 0615-8524
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 0615-8524). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-1.jpg (Aripiprazole 8524 8525 10)
This chart shows the change in YGTSS total tic score from baseline over several weeks of treatment. The graph compares the effects of Aripiprazole Low, Aripiprazole High, and Placebo on tic scores, with the y-axis representing the change in total tic score and the x-axis representing the weeks of treatment. The data indicates that Aripiprazole Low and Aripiprazole High resulted in a decrease in tic scores compared to Placebo.*
Principal Display Panel (Aripiprazole 8524 8525 11)
This entry is related to the medication Aripiprazole in tablet form, with a strength of 2 mg per tablet. The manufacturer listed is Dr. Reddy's, with packaging by VANGARD. The tablets contain USP-grade Aripiprazole and should be stored in tightly closed containers at a temperature of 25°C. The dosage recommendations are specified in the package insert. The text also mentions that it is for institutional use only.*
Principal Display Panel (Aripiprazole 8524 8525 12)
This is a description of medication packaging for Aripiprazole tablets. The tablets are each 10 mg and are manufactured for Dr. Reddy's. The package contains multiple tablets and is marked with the NDC number 0615852539. The tablets are to be stored in tightly closed containers at room temperature. The usual dosage information can be found in the package insert. This pharmaceutical product is for institutional use only.*
Figure-1.jpg (Aripiprazole 8524 8525 2)
This text provides information on the effect of other drugs on aripiprazole. It lists different drug categories like CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, and gastric acid blockers, along with specific drugs such as ketoconazole, quinidine, and carbamazepine. The text also mentions a change in relative to the reference without interacting drugs. Overall, this information can be valuable for understanding potential interactions and effects when combining aripiprazole with other medications.*
Figure-2.jpg (Aripiprazole 8524 8525 3)
This text provides information on the effect of other drugs, such as carbamazepine, gastric acid blockers, valproate, and lorazepam, on the medication Aripiprazole. It includes data on Dehydro-Aripiprazole Fold Change and 90% CI as well as Change Relative to Reference when interacting with the mentioned drugs. This information can be useful for understanding potential interactions and effects of combining Aripiprazole with other medications.*
Figure-3.jpg (Aripiprazole 8524 8525 4)
Description: The text provides information on the effect of Aripiprazole on various drugs such as dextromethorphan, venlafaxine, lamotrigine, omeprazole, and escitalopram. It also includes details on fold change and 90% confidence intervals related to the interaction with Aripiprazole.*
Figure-4.jpg (Aripiprazole 8524 8525 5)
This text seems to be discussing the effects of different factors such as gender, age, hepatic impairment, and renal impairment on the pharmacokinetics and pharmacodynamics of a drug named Avipiprazole. The text includes comparisons between groups in terms of area under the curve (AUC), maximum concentration (Cmax), and maximum effect (Emax). It also mentions the percentage change and confidence intervals for Avipiprazole.*
Figure-5.jpg (Aripiprazole 8524 8525 6)
Figure-6.jpg (Aripiprazole 8524 8525 7)
This document provides data on the proportion of subjects experiencing relapse over time with the use of Aripiprazole compared to a placebo. It includes the number of subjects at risk at different time points following randomization. Aripiprazole subjects start with 148 and decrease over time, while placebo subjects start with 149 and decrease similarly. The data is presented over a period of 182 days.*
Figure 7 (Aripiprazole 8524 8525 8)
This appears to be a table showing the proportion of subjects with relapse over time for a study comparing Aripiprazole and Placebo. The number of subjects at risk is provided for both groups at different time points. The data also includes the number of days from randomization.*
Figure 8 (Aripiprazole 8524 8525 9)
This text provides data on the proportion of subjects experiencing a relapse when treated with Aripiprazole compared to Placebo. The number of subjects at risk is also shown for each treatment group over different days from randomization. The information can be used for evaluating the effectiveness and safety of Aripiprazole in preventing relapse compared to Placebo treatment.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
